Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellular Biomedicine Group Inc Announces Appointment of Dr. Wei Cao as Chief Executive Officer-Form 8-K


Wednesday, 2 Oct 2013 02:09pm EDT 

Cellular Biomedicine Group Inc reported in its Form 8-K that On September 30, 2013, board of directors (the Board) promoted Dr. Wei (William) Cao to the position of Chief Executive Officer of Cellular Biomedicine Group, Inc. (the Company). Mr. Cao previously served the Company as its President, Chief Operating Officer and Director where he has directly responsible for research and development, clinical trial and supply chain management and manufacturing for the Company’s cytotherapy business. As CEO, Mr. Cao will assume the role of Principal Executive Officer as defined in the U.S. Securities and Exchange Commission (SEC) rules for SEC filing purposes and will continue his role as a director on the Company’s Board. Concurrently Dr. Wen Tao (Steve) Liu will step down as Chief Executive Officer effective September 30, 2013, and will continue his leadership role at the Company as President – North America, and as Chairman of the Board. In his new role, Mr. Liu will focus on the Company’s strategy in the United States and Canada.